7,093 Shares in Merit Medical Systems, Inc. $MMSI Purchased by Inceptionr LLC

Inceptionr LLC purchased a new stake in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 7,093 shares of the medical instruments supplier’s stock, valued at approximately $489,000.

Other hedge funds also recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC bought a new stake in shares of Merit Medical Systems in the fourth quarter worth approximately $25,000. Maseco LLP bought a new position in Merit Medical Systems during the fourth quarter valued at approximately $26,000. Torren Management LLC bought a new position in Merit Medical Systems during the fourth quarter valued at approximately $38,000. Covestor Ltd boosted its holdings in Merit Medical Systems by 252.6% in the fourth quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 336 shares during the last quarter. Finally, Danske Bank A S purchased a new stake in Merit Medical Systems in the third quarter worth approximately $42,000. 99.66% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Merit Medical Systems

In other news, Director Lynne N. Ward sold 5,000 shares of Merit Medical Systems stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $62.61, for a total transaction of $313,050.00. Following the completion of the sale, the director owned 7,809 shares of the company’s stock, valued at approximately $488,921.49. The trade was a 39.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Brian G. Lloyd bought 2,000 shares of the stock in a transaction on Thursday, May 7th. The stock was purchased at an average price of $62.62 per share, with a total value of $125,240.00. Following the completion of the acquisition, the insider directly owned 2,000 shares in the company, valued at approximately $125,240. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.70% of the company’s stock.

Merit Medical Systems Stock Up 1.7%

Shares of MMSI stock opened at $74.32 on Friday. The company’s fifty day simple moving average is $68.19 and its two-hundred day simple moving average is $72.13. Merit Medical Systems, Inc. has a 52 week low of $59.74 and a 52 week high of $94.75. The stock has a market cap of $4.43 billion, a P/E ratio of 32.17, a PEG ratio of 2.31 and a beta of 0.52. The company has a quick ratio of 3.46, a current ratio of 5.08 and a debt-to-equity ratio of 0.45.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.10. The company had revenue of $381.88 million for the quarter, compared to analysts’ expectations of $377.59 million. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. Merit Medical Systems’s quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.86 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. Analysts predict that Merit Medical Systems, Inc. will post 3.62 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on MMSI shares. Barrington Research dropped their target price on Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating on the stock in a research report on Monday, April 20th. Compass Point set a $107.00 price objective on shares of Merit Medical Systems in a research note on Monday, April 20th. Citigroup reissued an “outperform” rating on shares of Merit Medical Systems in a report on Monday, April 20th. JPMorgan Chase & Co. cut their target price on shares of Merit Medical Systems from $95.00 to $77.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Finally, Wells Fargo & Company reduced their target price on shares of Merit Medical Systems from $78.00 to $74.00 and set an “equal weight” rating for the company in a report on Friday, May 1st. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $92.80.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.